dapagliflozin

Also Known As:

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; BMS 512148; BMS-512148; BMS512148; Farxiga; Forxiga

Networked: 1762 relevant articles (303 outcomes, 684 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzhydryl Compounds
        dapagliflozin: 1762
Carbohydrates: 22023
- Glycosides: 2119
  - Glucosides: 639
    - dapagliflozin: 1762

Experts

1.	Langkilde, Anna Maria: 78 articles (08/2022 - 03/2012)
2.	Sabatine, Marc S: 60 articles (08/2022 - 01/2018)
3.	McMurray, John J V: 58 articles (08/2022 - 01/2019)
4.	Heerspink, Hiddo J L: 51 articles (08/2022 - 05/2017)
5.	Kosiborod, Mikhail N: 43 articles (09/2022 - 01/2019)
6.	Solomon, Scott D: 39 articles (08/2022 - 01/2019)
7.	Inzucchi, Silvio E: 38 articles (09/2022 - 01/2019)
8.	Jhund, Pardeep S: 37 articles (08/2022 - 11/2019)
9.	Sjöström, C David: 36 articles (04/2022 - 09/2015)
10.	Køber, Lars: 34 articles (08/2022 - 01/2019)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 11/08/2023 - "Dapagliflozin was associated with significant and clinically meaningful improvement in echocardiographic parameters versus placebo in patients with type 2 diabetes and HFrEF.Registration" 01/01/2020 - "Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus. " 01/01/2018 - "Dapagliflozin significantly improved treatment satisfaction among patients with type 2 diabetes mellitus for 14 weeks. " 01/01/2012 - "Dapagliflozin appears effective in reducing HbA1c and weight in type 2 diabetes, although more safety data are needed." 01/01/2022 - "Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus."
2.	Heart Failure 02/01/2023 - "The DELIVER study recently confirmed a significant reduction in the composite outcome hHF plus cardiovascular mortality (- 27 %) and in hHF (- 21 %) in patients (with or without T2DM) with heart failure and mildly reduced or preserved LVEF treated with dapagliflozin compared with placebo. " 03/01/2023 - "Dapagliflozin, a new treatment option for heart failure, leads to a significant reduction in the hospitalization of patients with heart failure. " 01/01/2022 - "Dapagliflozin (DAPA) has been reported to have significant cardiac protective effects on heart failure (HF). " 01/01/2021 - "In HFrEF subgroup, dapagliflozin was associated with a reduced incidence of hospitalization for heart failure (n=4, OR=0.74; 95% CI, 0.60 to 0.91; I2 = 0%), cardiovascular death (n=4, OR=0.72; 95% CI, 0.58 to 0.91; I2 = 8%), and all-cause mortality (n=3, OR=0.70; 95% CI, 0.50 to 0.99; I2 = 43%) without significant heterogeneity. " 01/01/2020 - "Dapagliflozin significantly improved RVSP and LVFP during exercise in patients with T2DM and cardiovascular risk, which may contribute to favorable effects on heart failure."
3.	Body Weight (Weight, Body) 01/01/2022 - "After 120 days of treatment with dapagliflozin, a statistically significant reduction in weight, body mass index (BMI), body fat, circumferences, and all skinfold thickness was seen. " 01/01/2021 - "Pooled results of this meta-analysis identified a significant reduction in HbA1c levels, body weight, and TDID, and a substantial increase in 24-h UGE in patients who received dapagliflozin versus placebo." 07/01/2018 - "At Week 24, compared with placebo, dapagliflozin significantly improved HbA1c (mean [95% confidence interval] 0.03% [-0.11, 0.17] for placebo vs -0.87% [-1.00, -0.74] for dapagliflozin; between-group difference - 0.90% [-1.09, -0.71], P < 0.0001]), FPG, body weight, TDDI, and SeSBP. " 01/01/2016 - "The long-term efficacy of dapagliflozin to maintain reductions in HbA1c, SBP and body weight over 2 years, together with its tolerability profile, make dapagliflozin an appropriate option in high-risk patients with T2DM and CVD." 11/01/2015 - "Significantly greater reductions in FPG level, 2-h PPG level, and body weight were observed, and more patients achieved an HbA1c level of <7% (53 mmol/mol) with treatment with dapagliflozin versus placebo. "
4.	Weight Loss (Weight Reduction) 01/01/2017 - "Dapagliflozin, when added in real life to patients with T2DM treated with GLP1-RAs, induced a further significant, albeit modest improvement in A1C and a further weight loss." 06/01/2015 - "Dapagliflozin treatment is also associated with weight reduction and a decrease in blood pressure, both of which may be beneficial in patients with T2DM. " 07/01/2014 - "Dapagliflozin patients had significantly greater weight loss than placebo patients over 102 weeks (p < 0.05). " 10/01/2012 - "Mean FPG reduction was significantly greater for all dapagliflozin groups versus placebo (p < 0.02), as was mean weight reduction (p < 0.003). " 07/01/2014 - "Dapagliflozin-induced weight loss was associated with improvement in overall HRQOL. "
5.	Insulin Resistance 12/20/2022 - "Hyperinsulinemic-euglycemic clamp test indicated that the insulin sensitivity index was significantly improved in the patient after taking oral dapagliflozin. " 02/01/2018 - "Low-grade ketonaemia after dapagliflozin treatment may also be associated with improved insulin sensitivity." 11/01/2010 - "Dapagliflozin improved insulin sensitivity index: 0.08 ± 0.01 vs. 0.02 ± 0.01 in obese controls (p < 0.03). " 07/01/2021 - "Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial." 07/01/2022 - "A Possible Novel Effect for Dapagliflozin in the Management of Subcutaneous Insulin Resistance Syndrome: A Report of Two Cases."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	empagliflozin
3.	Insulin (Novolin)
4.	Metformin (Glucophage)
5.	Sodium
6.	Sodium-Glucose Transporter 2 Inhibitors
7.	Canagliflozin
8.	Sodium-Glucose Transport Proteins
9.	Blood Glucose (Blood Sugar)
10.	Symporters

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Drug Therapy (Chemotherapy)
4.	Bariatric Surgery
5.	Renal Replacement Therapy (Therapies, Renal Replacement)